Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists Discover Key to Effective Meningitis Vaccine

10.03.2011
A study conducted by Children’s Hospital & Research Center Oakland and University of Massachusetts Medical Center scientists identifies a new mutant vaccine antigen for Neisseria meningitidis (also called meningococcus) that has the potential to improve vaccine development against dangerous bacterial infections including meningitis.

The study, authored by Children’s Hospital Oakland Research Institute (CHORI) scientists Dan Granoff, MD, and Peter Beernink, PhD, and colleagues at the University of Massachusetts Medical Center, Worcester MA, will be featured in the March 15, 2011 issue of the Journal of Immunology (published online February 16, 2011).

“It’s really quite gratifying to have a study like this that has direct translation into making better vaccines against infections, especially meningococcal disease,” said Dr. Granoff, Director of CHORI’s Center for Immunobiology and Vaccine Development. “This deadly disease affects hundreds of thousands of children throughout the world. Almost no other infection can kill a previously healthy child as fast as the meningococcus.”

Meningococci are bacteria responsible for causing meningitis and severe bloodstream infections. Young children and teenagers are particularly vulnerable. Even with the best treatment, 10 percent of those infected will not survive. About 20 percent of those who survive are left with long-term medical problems including loss of hearing, chronic seizures, and amputation of limbs.

While there are vaccines available for prevention of certain strains of the bacteria, there is no vaccine against “group B” strains, which account for approximately 40 percent of cases in the United States. Currently, there are two vaccines targeting group B strains in development. These vaccines utilize a novel antigen called factor H-binding protein (fHbp) to stimulate human immune responses against the bacteria. The fHbp antigen in the vaccines binds with human factor H (fH), a protein normally present in the bloodstream.

Dr. Granoff’s research, however, demonstrates that a simple change in the protein can greatly improve the efficacy of the vaccines. Because fH in animals differs from that in humans, genetically engineered mice were created in order to investigate the effect of fH binding on the fHbp vaccines.

A traditional animal study would not be able to capture the effects of this because fH in animals is slightly different than it is in humans. Dr. Granoff and his team got some help from genetically engineered mice.

When the mice with human fH (created by Sanjay Ram, MD, and Peter Rice, MD, at the University of Massachusetts in Worcester) were immunized, the fHbp antigen vaccine worked well in normal mice whose fH didn’t bind to the vaccine. But in the mice with human fH, the protective ability of the vaccine dropped four- to eight-fold. The more human fH a mouse had, the worse the level of protection the vaccine provided.

The same study, however, demonstrated a solution: Dr. Granoff and his colleagues showed that using an fHbp antigen with a slight mutation resulted in significant increases in protection.

“This mutant antigen has just one amino acid difference between it and the fHbp in the current vaccines, but that difference means that it no longer binds to human fH, and that resulted in much higher protective responses,” said Dr. Granoff.

In addition to significantly improving the current meningitis vaccines, the study also provides proof of principle that has the potential to be applied to vaccines against other bacteria that also utilize fH binding, like pneumococcus and Bordatella.

“Our study suggests that while a vaccine that actually targets fH binding proteins offers a unique opportunity to prevent disease, you probably need to develop forms of the vaccine that don’t bind to the host protein, said Dr. Granoff. “What we need to be looking for are mutants that make the antigen look like the fH binding proteins, but that remove the binding function.”

The study provides a solid foundation for the development of second generation meningococcal vaccines while also providing an approach for creating highly effective vaccines against other infectious bacteria.

About Children’s Hospital & Research Center Oakland
Children’s Hospital & Research Center Oakland is Northern California’s only independent not-for-profit regional medical center for children. Children’s Hospital Oakland is a national leader in many pediatric specialties and sub-specialties including hematology/oncology, neonatology, cardiology, orthopedics, sports medicine, and neurosurgery. The hospital is one of only two solely designated California Level 1 pediatric trauma centers with the largest pediatric inpatient critical care unit in the region. Children’s Hospital has 190 licensed beds, 201 hospital-based physicians in 30 specialties, more than 2,700 employees, and an annual operating budget of more than $350 million. Children’s is also a premier teaching hospital with an outstanding pediatric residency program and unique pediatric subspecialty fellowship programs.

Children’s research program, Children’s Hospital Oakland Research Institute (CHORI), is internationally renowned for taking state-of-the-art basic and clinical research and translating it into interventions for treating and preventing human diseases. CHORI has 300 members of its investigative staff, a budget of about $50 million, and is ranked among the nation’s top 10 research centers in National Institutes of Health funding to children’s hospitals. For more information, go to www.childrenshospitaloakland.org and www.chori.org.

Erin Goldsmith | Newswise Science News
Further information:
http://www.chori.org

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>